A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to ...

RCC trials are predominantly in high-income countries, limiting access for lower-income patients and affecting global treatment strategies. Minority groups, especially Black and Hispanic ...

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification. The phase 3 COSMIC-313 trial evaluated Cabometyx ...

Night - Scattered showers with a 52% chance of precipitation. Winds E. The overnight low will be 70 °F (21.1 °C). Mostly cloudy with a high of 75 °F (23.9 °C) and a 68% chance of precipitation ...

Commissions do not affect our editors' opinions or evaluations. Hotel credit cards aren’t for everyone, but they can make a lot of sense to those who are loyal to a specific brand. Cardholders ...

Alan Tan, MD, assistant professor of medicine in the division of hematology and oncology at Vanderbilt University Medical Center, discusses potential biomarkers that are being investigated to optimize ...

Recent analyses have shown a stark imbalance in the distribution and access to renal cell carcinoma (RCC) clinical trials, with the studies conducted heavily skewed toward high-income countries.

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...